This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - boceprevir for the treatment of genotype 1 chronic hepatitis C

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:

  • who are previously untreated or in whom previous treatment has failed

Notes:

  • Boceprevir is a NS3/4A serine protease inhibitor that is administered orally
    • NS3/ 4A serine protease is essential for viral replication and may be partially responsible for the ability of the hepatitis C virus (HCV) to evade clearance by the host immune system
    • Boceprevir has a UK marketing authorisation 'for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy'

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page